Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO-LT Phase 3, Open-Label Study

The study evaluated the long-term efficacy and safety of ritlecitinib in treating alopecia areata (AA) over 3 years, involving 191 patients aged 12 years and older with significant scalp hair loss. Results showed that 65.1% of observed patients and 47.1% using the last observation carried forward (LOCF) method achieved a Severity of Alopecia Tool (SALT) score of ≤20. Additionally, 52.3% of observed patients and 36.7% using LOCF achieved a SALT score of ≤10. Patient-reported improvements were noted, with 68.4% of observed patients and 55.6% using LOCF reporting moderate to great improvement. The findings support the long-term use of ritlecitinib for AA treatment.